Oncotarget

Research Papers:

Importance of the plasma soluble HLA-G levels for prognostic stratification with traditional prognosticators in colorectal cancer

Jing-Bo Li, Yan-Yun Ruan, Bin Hu, Shan-Shan Dong, Tie-Nan Bi, Aifen Lin and Wei-Hua Yan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:48854-48862. https://doi.org/10.18632/oncotarget.16457

Metrics: PDF 1783 views  |   HTML 2520 views  |   ?  


Abstract

Jing-Bo Li1, Yan-Yun Ruan2, Bin Hu1, Shan-Shan Dong2, Tie-Nan Bi3, Aifen Lin2 and Wei-Hua Yan1,4

1Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China

2Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China

3Department of Gastrointestinal Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China

4Department of Laboratory Medicine, Xianju People’s Hospital, Xianju, Zhejiang, People’s Republic of China

Correspondence to:

Wei-Hua Yan, email: [email protected]

Aifen Lin, email: [email protected]

Keywords: soluble HLA-G, colorectal cancer, prognosis

Received: November 07, 2016     Accepted: March 13, 2017     Published: March 22, 2017

ABSTRACT

An increased peripheral soluble HLA-G (sHLA-G) expression has been observed in various malignancies while its prognostic significance was rather limited. In this study, the prognostic value of plasma sHLA-G in 178 colorectal cancer (CRC) patients was investigated. sHLA-G levels were analyzed by specific enzyme-linked immunosorbent assay. Data showed sHLA-G levels were significantly increased in CRC patients compared with normal controls (36.8 U/ml vs 25.4 U/ml, p = 0.009). sHLA-G in the died were obviously higher than that of alive CRC patients (46.8 U/ml vs 27.4 U/ml, p = 0.012). Patients with sHLA-G above median levels (≥ 36.8 U/ml, sHLA-Ghigh) had a significantly shorter survival time than those with sHLA-Glow (< 36.8 U/ml, p < 0.001), and sHLA-G could be an independent prognostic factor for CRC patients. With stratification of clinical parameters in survival by sHLA-Glow and sHLA-Ghigh, sHLA-G exhibited a significant predictive value for CRC patients of the female (p = 0.036), the elder (p = 0.009), advanced tumor burden (T3 + 4, p = 0.038), regional lymph node status (N0, p = 0.041), both metastasis status (M0, p = 0.014) and (M1, p=0.018), and clinical stage (I + II, p = 0.018), respectively. Summary, our data demonstrated for the first time that sHLA-G levels is an independent prognosis factor and improves the prognostic stratification offered by traditional prognosticators in CRC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16457